Search

Displaying results 2301 - 2310 of 2674 in total
  1. Target

    T-cell surface glycoprotein CD3 delta chain

    go.drugbank.com/bio_entities/BE0003456
    TargetHumans

    When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z.

    Synonyms: T-cell receptor T3 delta chain
  2. Target

    T-cell surface glycoprotein CD3 gamma chain

    go.drugbank.com/bio_entities/BE0003457
    TargetHumans

    Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G … When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z.

    Synonyms: T-cell receptor T3 gamma chain
  3. Target

    P2Y purinoceptor 4

    go.drugbank.com/bio_entities/BE0009822
    TargetHumans

    Receptor for UTP and UDP coupled to G proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP

    Synonyms: Uridine nucleotide receptorFunction: G protein-coupled purinergic nucleotide receptor activity
  4. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.

  5. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  6. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  7. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … [L47122] In June 2023, Rozanolixizumab-noli was approved by the FDA under Priority Review for the treatment of adult patients with generalized myasthenia gravis who are positive for the anti-acetylcholine

    Categories: Neonatal Fc Receptor Blocker
  8. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  9. Drug

    Otilimab

    go.drugbank.com/drugs/DB06303
    Investigational

    Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).

  10. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). … Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.